West Pharmaceutical Services, Inc. $WST Position Decreased by Seilern Investment Management Ltd

Seilern Investment Management Ltd decreased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 24.2% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 326,957 shares of the medical instruments supplier’s stock after selling 104,604 shares during the quarter. West Pharmaceutical Services accounts for approximately 6.3% of Seilern Investment Management Ltd’s portfolio, making the stock its 7th largest position. Seilern Investment Management Ltd owned about 0.45% of West Pharmaceutical Services worth $85,771,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of the stock. CYBER HORNET ETFs LLC purchased a new position in West Pharmaceutical Services in the 2nd quarter worth approximately $25,000. Quarry LP purchased a new stake in shares of West Pharmaceutical Services during the 1st quarter valued at $27,000. Vermillion & White Wealth Management Group LLC lifted its holdings in shares of West Pharmaceutical Services by 193.9% during the 2nd quarter. Vermillion & White Wealth Management Group LLC now owns 144 shares of the medical instruments supplier’s stock worth $32,000 after acquiring an additional 95 shares during the last quarter. CVA Family Office LLC grew its position in West Pharmaceutical Services by 573.3% in the second quarter. CVA Family Office LLC now owns 202 shares of the medical instruments supplier’s stock worth $44,000 after acquiring an additional 172 shares in the last quarter. Finally, MUFG Securities EMEA plc purchased a new position in West Pharmaceutical Services in the second quarter worth $47,000. 93.90% of the stock is owned by hedge funds and other institutional investors.

West Pharmaceutical Services Price Performance

WST opened at $272.31 on Monday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.87 and a quick ratio of 2.18. The stock’s 50 day simple moving average is $274.12 and its 200 day simple moving average is $252.50. The firm has a market cap of $19.59 billion, a price-to-earnings ratio of 40.34, a PEG ratio of 4.21 and a beta of 1.17. West Pharmaceutical Services, Inc. has a 1 year low of $187.43 and a 1 year high of $348.90.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings data on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.29. West Pharmaceutical Services had a return on equity of 18.16% and a net margin of 16.29%.The firm had revenue of $804.60 million during the quarter, compared to analyst estimates of $788.42 million. During the same quarter in the prior year, the firm posted $1.85 earnings per share. The business’s quarterly revenue was up 7.7% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. As a group, analysts predict that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, February 4th. Shareholders of record on Wednesday, January 28th will be issued a $0.22 dividend. This represents a $0.88 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Wednesday, January 28th. West Pharmaceutical Services’s dividend payout ratio (DPR) is 13.04%.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on WST. Evercore ISI lifted their price target on West Pharmaceutical Services from $350.00 to $390.00 and gave the stock an “outperform” rating in a research note on Thursday, October 23rd. Rothschild & Co Redburn initiated coverage on West Pharmaceutical Services in a report on Monday, September 15th. They set a “buy” rating and a $311.00 price objective on the stock. Deutsche Bank Aktiengesellschaft set a $345.00 target price on West Pharmaceutical Services and gave the stock a “buy” rating in a research note on Friday, October 24th. Cowen assumed coverage on shares of West Pharmaceutical Services in a research report on Wednesday, October 29th. They set a “buy” rating on the stock. Finally, TD Cowen assumed coverage on shares of West Pharmaceutical Services in a research note on Wednesday, October 29th. They set a “buy” rating and a $350.00 price target on the stock. Two investment analysts have rated the stock with a Strong Buy rating, eight have assigned a Buy rating and four have given a Hold rating to the company’s stock. According to data from MarketBeat, West Pharmaceutical Services has an average rating of “Moderate Buy” and a consensus target price of $342.20.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.